

1. BSI 2023 Poster P-570. D. Fraser-Pitt, S. Knight, D. Mercer, M-L. Francis, D. T. Aparicio, D. Smith and D. O'Neil. A druggable link between glycine metabolism and innate immunity to viral infection.
2. Douglas Fraser-Pitt, Derry K Mercer, Marie-Louise Francis, David Toledo-Aparicio, Daniel W Smith, Deborah A O'Neil. Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection. *Biochemical and Biophysical Research Communications*, Vol. 677, 15 Oct 2023
<https://doi.org/10.1016/j.bbrc.2023.08.021>
3. ECCMID 2022 Poster 04497. D. Fraser-Pitt, D. Mercer, M-L. Francis, D. T. Aparicio and D. O'Neil. Glycine decarboxylase (GLDC) inhibition by cysteamine, a phase III clinical candidate intervention for community-acquired pneumonia (CAP), potentiates the host response to respiratory viruses, including SARS-CoV-2, via pyrimidine restriction.
4. ECCMID 2022 Poster 04498. D. Fraser-Pitt, J. G. Hunt, D. T. Aparicio, T. Stoyanova, D. Mercer and D. O'Neil. Cysteamine, a phase III clinical candidate intervention for community-acquired pneumonia (CAP) improves antibiotic-mediated protection from death in *C. elegans* infected with antibiotic-resistant strains of bacteria commonly associated with pneumonia.
5. ECCMID 2022 Poster 04448. D. Smith, L. Simpson, E. Lovie and D.O'Neil. NP339; A Therapeutic Candidate for Respiratory Fungal Infection.
6. ECCMID 2022 Poster 04746. D. Smith, L. Simpson, E. Lovie, L. Katvars and D. O'Neil. NP339, a Novel Membrane Active Antifungal Candidate is not Cytotoxic or Haemolytic *in vitro*.
7. NACFC 2021 Poster 524 NM001. S. Dolan, D. Fraser-Pitt and D. O'Neil. Transcriptomic analysis on the effects of cysteamine on the virulence and metabolism of *Pseudomonas aeruginosa* and *Burkholderia cenocepacia*. [https://doi.org/10.1016/S1569-1993\(21\)01948-2](https://doi.org/10.1016/S1569-1993(21)01948-2)
8. NACFC 2021 Poster 431 NM001. D. Fraser-Pitt, S. Dolan, D. Smith and D. O'Neil. Antivirulence activities of cysteamine and protection from *Pseudomonas* toxicity in the *Galleria mellonella* model
[https://doi.org/10.1016/S1569-1993\(21\)01855-5](https://doi.org/10.1016/S1569-1993(21)01855-5)
9. TIMM 2021 Poster P339. D. W. Smith, E. Lovie, L. Simpson and D. A. O'Neil. Novel antifungal peptide NP339 inhibits *A. fumigatus* growth in whole human blood.
<https://timm2021.navus.io/presentation/84316>
10. Douglas J Fraser-Pitt, Stephen K Dolan, David Toledo-Aparicio, Jessica G Hunt, Daniel W Smith, Niamh Lacy-Roberts, Piumi Sara Nupe Hewage, Teodora N Stoyanova, Erin Manson, Kevin McClean, Neil F Inglis, Derry K Mercer, Deborah A O'Neil. Cysteamine inhibits glycine utilisation and disrupts virulence in *Pseudomonas aeruginosa*. *Front Cell Infect Microbiol*. 22 Sep 2021
<https://doi.org/10.3389/fcimb.2021.718213>
11. Derry K Mercer, Marie-Louise Francis and Douglas Fraser-Pitt. Antimicrobial immunotherapeutics: past, present and future. *Emerging Topics in Life Sciences*. 1 Jul 2021
<https://doi.org/10.1042/ETLS20200348>
12. Marita Meurer, Deborah A O'Neil, Emma Lovie, Laura Simpson, Marcelo D.T. Torres, Cesar de la Fuente-Nunez, Alfredo M Angeles-Boza, Christin Kleinsorgen, Derry K Mercer and Maren von Köckritz-Blickwede. Antimicrobial Susceptibility Testing of Antimicrobial Peptides Requires New and Standardized Testing Structures. *American Chemical Society Infectious Diseases*. 10 June 2021.
<https://doi.org/10.1021/acsinfecdis.1c00210>
13. Vanessa Duncan, Daniel Smith, Laura Simpson, Emma Lovie, Laura Katvars, Leon Berge, Jennifer Robertson, Shane Smith, Carol Munro, Derry Mercer and Deborah O'Neil. Preliminary

- Characterisation of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity. *ASM Antimicrobial Agents and Chemotherapy*. 24 May 2021 <https://doi.org/10.1128/AAC.02345-20>
14. Douglas Fraser-Pitt and Derry Mercer. What role for cysteamine in the defence against infection? *Emerging Topics in Life Sciences*. 24 May 2021 <https://doi.org/10.1042/ETLS20200351>
 15. Deborah A. O'Neil. Innovation in infectious disease therapies from immunology. *Drug Discovery Today*. 31 March 2021 <https://doi.org/10.1016/j.drudis.2021.03.023>
 16. Graham Devereux, Danielle Wrolstad, Stephen J Bourke, Cori L Daines, Simon Doe, Ryan Dougherty, Rose Franco, Alastair Innes, Benjamin T Kopp, Jorge Lascano, Daniel Layish, Gordon MacGregor, Lorna Murray, Daniel Peckham, Vincenzina Lucidi, Emma Lovie, Jennifer Robertson, Douglas J Fraser-Pitt and Deborah A O'Neil. Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: an exploratory randomized clinical trial. *PLOS ONE*. 28 December 2020 <https://doi.org/10.1371/journal.pone.0242945>
 17. D.K. Mercer and D.A. O'Neil. Innate Inspiration: The search for novel antifungal therapeutics from the host immune response. *Frontiers Immunol*. 17 September 2020 <https://doi.org/10.3389/fimmu.2020.02177>. Article also featured in Editorial: Advances in the Immunology of Host Defense Peptide: Mechanisms and Applications of Antimicrobial Functions and Beyond. *Frontiers Immunol*. 25 February 2021 <https://doi.org/10.3389/fimmu.2021.637641>
 18. Derry K Mercer, Marcelo Der Torossian Torres, Searle S Duay, Emma Lovie, Laura Simpson, Maren von Köckritz-Blickwede, Cesar de la Fuente-Nunez, Deborah A O'Neil, Alfredo M Angeles-Boza. (2020). Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy. *Frontiers in Cellular and Infection Microbiology*. Volume 10, Article 326. <https://doi.org/10.3389/fcimb.2020.00326>
 19. Mercer DK, Robertson J, Miller L, Stewart CS, O'Neil DA. (2020). NP213 (Novexatin): A unique therapy candidate with a differentiated safety and efficacy profile. *Medical Mycology*, Vol 58, Issue 8, November 2020, Pages 1064-1072 <https://doi.org/10.1093/mmy/myaa015>.
 20. ECCMID 2020 Poster L0113. D. W. Smith, L. K. Katvars and D. A. O'Neil. *In vivo* efficacy of NP339 against Invasive Pulmonary Aspergillosis (IPA)
 21. G. Devereux, S. Bourke, C. Daines, S. Doe R. Dougherty, R. Franco, A. Innes, B. Kopp, J. Lascano, D. Layish, G. McGregor, L. Murray. D. Peckham, T. Smith, V. Lucidi, S. Volpi, E. Lovie, J. Robertson, D. Fraser-Pitt, D. O'Neil. Evaluating appropriate PROMs in CARE CF 1 trial: Lynovex (cysteamine) as an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. *J Cystic fibrosis*, June 2019; 18, supp1, S23. [https://doi.org/10.1016/S1569-1993\(19\)30191-2](https://doi.org/10.1016/S1569-1993(19)30191-2)
 22. D. Fraser-Pitt, D. Smith, P. Perenyi and D O'Neil. Cysteamine impairs lipoic acid cofactors-mediated aspects of bacterial metabolism in cystic fibrosis pathogens. *J Cystic fibrosis*, June 2019; 18, supp1, S90.
 23. Mercer DK, Stewart CS, Miller L, Robertson J, Duncan VMS, O'Neil DA. (2019). Improved methods for assessing therapeutic potential of antifungal agents against dermatophytes and their application in the development of NP213, a novel onychomycosis therapy candidate. *Antimicrob Agents Chemother* 63:e02117-18. <https://doi.org/10.1128/AAC.02117-18>
 24. Devereux G, Fraser-Pitt D, Robertson J, Devlin E, Mercer D, O'Neil D. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum. *EBioMedicine*. 2015 Aug 10;2(10):1507-12. <https://doi.org/10.1016/j.ebiom.2015.08.018>

25. NACFC Poster 494 (2019). D. Fraser-Pitt¹, Daniel Smith¹, P. Perenyi, Deborah A. O'Neil¹. Cysteamine disrupts key aspects of metabolism in *P. aeruginosa*.
26. NACFC Poster 499 (2019). D. Fraser Pitt, Niamh Lacy Roberts, Piumi Sara Nupe Hewage, Daniel Smith, Deborah A. O'Neil. Cysteamine inhibits multiple virulence traits of CF-associated pathogens.
27. NACFC Poster 2019. D. Fraser-Pitt¹, Deborah A. O'Neil. The effect of cysteamine formulated for dry powder inhalation (DPI) on cystic fibrosis sputum rheology.
28. ECFS Poster P111 (2019). D. Fraser-Pitt, D. Smith, D. O'Neil. Cysteamine has wide-ranging anti-virulence properties against cystic fibrosis pathogens. [https://doi.org/10.1016/S1569-1993\(19\)30405-9](https://doi.org/10.1016/S1569-1993(19)30405-9)
29. ECFS Poster P114 (2019). D. Fraser-Pitt, D. Smith, P. Perenyi, D. O'Neil. Cysteamine impairs lipoic acid cofactor-mediated aspects of bacterial metabolism in CF pathogens. [https://doi.org/10.1016/S1569-1993\(19\)30408-4](https://doi.org/10.1016/S1569-1993(19)30408-4)
30. ECFS Care-CF-1 Poster (2019). G. Devereux¹, S. Bourke², C. Daines³, S. Doe⁴, R. Dougherty⁵, R. Franco⁶, A. Innes⁷, B. Kopp⁸, J. Lascano⁹, D. Layish¹⁰, G. McGregor¹¹, L. Murray¹², D. Peckham¹³, T. Smith¹⁴, V. Lucidi¹⁵, S. Volpi¹⁶, E. Lovie¹⁷, J. Robertson¹⁷, D. Fraser-Pitt¹⁷, D. O'Neil¹⁷. Patient reported outcome measures in CARE-CF-1 TRIAL.
31. DDL Poster 2019. Andrew Naylor, Deborah O'Neil, Douglas Fraser-Pitt, Laura Mason & Richard Johnson. Novel Inhaled Treatment for Cystic Fibrosis, Manufactured Using a Combination Process of Spray Drying and Micronisation.
32. Douglas Fraser-Pitt, D K Mercer, D Smith, A Kowalczyk, J Robertson, E Lovie, P Perenyi, M Cole, M Doumith, R L R Hill, K L Hopkins, N Woodford, D A O' Neil. Cysteamine, an endogenous aminothioliol, and cystamine, the disulfide product of oxidation, increase *Pseudomonas aeruginosa* sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection. Mar 2018. *Infec Immun* 10.1128/IAI.00947-17. <https://www.ncbi.nlm.nih.gov/pubmed/29581193>
33. NACFC Poster 296 (2018). D. Fraser-Pitt¹, Andrew Strange², Sandra Steele², Kairen Griffiths², Devereux, Graham³, 2, Deborah A. O'Neil¹. Cysteamine Rapidly Binds Susceptible Cysteines in Gel-forming Mucins to Break Polymers in Cystic Fibrosis Sputum
34. NACFC Poster 298 (2018). G Devereux², SJ Bourke³, C Daines⁴, S Doe³, R Dougherty⁵, R Franco⁶, A Innes⁷, BT Kopp⁸, J Lascano⁹, D Laysih¹⁰, G McGregor¹¹, L Murray¹², D Peckham¹³, T Smith¹⁴, V Lucidi¹⁵, S Volpi¹⁶, E Lovie¹, J Robertson¹, DJ Fraser-Pitt¹, DA O'Neil¹. CARE-CF-1 Trial: Cysteamine, in Acute Respiratory Exacerbations of Cystic Fibrosis.
35. IMAP 2018 poster. Manal M Alsaadi 1, 2, Vanessa MS Duncan 1, Alexander B Mullen 2 and Deborah A O'Neil. The Antifungal Activity of Novel Formulations Containing Novamycin®
36. D Fraser-Pitt, D Mercer, E Lovie, P Perenyi, D O'Neil. Mechanisms of Action of Cysteamine: A late stage candidate therapy for CF. *Pediatr Pulmonol Suppl.* 52: S1-S776
37. L Katvars, D Smith, V Duncan, S Smith, D Mercer, K Holden, P Warn, D O'Neil. A novel peptide antifungal approach against respiratory fungal infections. *Pediatr Pulmonol Suppl.* 52: S1-S776
38. ASM-ICAAC 2017 poster.
39. ASM 2017- D K Mercer, L Katvars, F Hewitt, D Smith, J Robertson, D A O'Neil. NP108, an Antimicrobial Polymer with Activity against Methicillin – and Mupirocin – Resistant *Staphylococcus aureus*. Jun 2017.

40. D Fraser-Pitt, E Lovie, J Robertson, D A O'Neil. 59 Cysteamine inhibits neutrophil elastase activity. Jun 2017. *Journal of Cystic Fibrosis* 16(1):S79
41. V M S Duncan, L Katvars, K A Holden, P Warn, D A O'Neil. WS07.3 Antifungal activity of inhaled NP339 in vivo in respiratory models of *Aspergillus fumigatus* infection. Jun 2017. *Journal of Cystic Fibrosis* 16(1):S12 [https://doi.org/10.1016/S1569-1993\(17\)30196-0](https://doi.org/10.1016/S1569-1993(17)30196-0)
42. ECCMID 2017 poster – D Mercer, V Duncan, L Katvars, D Smith, T Shaw, K Holden, D O'Neil. Antifungal activity of Novamycin (NP339) in vivo on Respiratory Models of fungal infection. https://www.escmid.org/research_projects/eccmid/past_eccmids/
43. ECCMID 2017- L Katvars, D. Smith, V Duncan, L Simpson, D. Fraser-Pitt, B. Enderby, N. Withers, C Sheldon, C. Auckland, P. Oades, D. O'Neil. Novamycin, (NP339) as a novel approach against respiratory fungal infections. https://www.escmid.org/research_projects/eccmid/past_eccmids/
44. ECCMID 2017- D. Fraser-Pitt, D Mercer, D Smith, J Robertson, E Lovie, M Cole, M Doumith, R Hill, K Hopkins, N Woodford, D O'Neil. Cysteamine, as an antibiotic resistance breaker. https://www.escmid.org/research_projects/eccmid/past_eccmids/
45. ECCMID 2017- L. Katvars, D Mercer, D O'Neil. Novarifyn (NP432), a novel antimicrobial peptide rapidly active against multi-drug resistant *Acinetobacter baumannii* and resistant *Staphylococcus aureus*. https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=51912
46. D. Mercer, L Katvars, F Hewitt, N Denholm, D Smith, J Robertson, D. O'Neil. NP108, an antimicrobial polymer with activity against Methicillin- and Mupirocin-Resistant *Staphylococcus aureus*. *June 2016. Antimicrobial Agents and Chemotherapy* 61(9):AAC. 00502-17 <https://doi.org/10.1128/AAC.00502-17>
47. D K Mercer, T Sairi, E Sroka, H Lamont, Y Lawrie and D A O'Neil. 2017. Expression of innate immune defence genes in healthy and onychomycotic nail and skin. *Br J Derm.* 177(1):279-281. <https://doi.org/10.1111/bjd.15063>
48. D Fraser-Pitt, D Mercer, E Lovie, J Robertson and D O'Neil. 2016. Activity of Cysteamine against the Cystic Fibrosis *Burkholderia cepacia* complex. *Antimicrob Agents Chemo.* 60(10):6200-6206. <https://doi.org/10.1128/AAC.01198-16>
49. ASM 2016 / ICAAC poster – D.K. Mercer, D. Fraser-Pitt, J Robertson, D O,Neil. Cysteamine as an antibiotic resistance breaker.
50. ECFS 2016 1- D Smith, V Duncan, T Young, L Katvars, D F Pitt, B J Enderby, N J Withers, C Sheldon, C Auckland, P J Oades, D A O'Neil. Novel approaches for CF associated respiratory fungal infections. Jun 2016. *Journal of Cystic Fibrosis* 15(1):S43
51. ECFS 2016 2 - D Mercer, J Robertson, D Fraser-Pitt, D A O'Neil. Potential use of Lynovex (Cysteamine) as an antibiotic resistance- breaker in the treatment of *Burkholderia cepacia* complex (Bcc) colonisation in cystic fibrosis. Jun 2016. *Journal of Cystic Fibrosis* 15(1):S48 .
52. ECFS 3 2016 - D. Fraser-Pitt, D.Smith, D. O'Neil. Inhaled Cysteamine for the Chronic Management and Symptomatic Control of CF Associated Lung Disease. *Jun 2016. Journal of Cystic Fibrosis.* 15 (1):S42
53. Graham Devereux, Sandra Steele, Karien Griffiths, Edward Devlin, Douglas Fraser Pitt, Seonaidh Cotton, John Norrie, Henry Chrystyn, Deborah A. O'Neil. An open label investigation of the

- pharmacokinetics and tolerability of oral cysteamine in adults with cystic fibrosis. 2016. *Clinical Drug Investigation*, 36(8), 605-612. <https://doi.org/10.1007/s40261-016-0405-z>
54. Douglas Fraser-Pitt and Deborah A O'Neil. Cystic Fibrosis - a multiorgan protein misfolding disease. 2015. *Future Sci. OA* (2015) FSO57. <https://doi.org/10.4155/fso.15.57>
55. Devereux G, Fraser-Pitt D, Robertson J, Devlin E, Mercer D, O'Neil D. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum. *EBioMedicine*. 2015 Aug 10;2(10):1507-12. <https://doi.org/10.1016/j.ebiom.2015.08.018>
56. E. Devlin, D. Fraser-Pitt, C. Munro and D. O'Neil. Interactions between cystic fibrosis and non-cystic fibrosis isolates of *Aspergillus fumigatus* and *Pseudomonas aeruginosa* in the development of a co-culture infection model for testing novel therapeutics. *J. Cystic Fibrosis*. 2015. 14; S63
57. G. Devereux, D. Fraser-Pitt, E. Devlin, J. Robertson, S. Steele, K. and D. O'Neil. An open-label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with cystic fibrosis. *J. Cystic Fibrosis*. 2015. 14; S93
58. Cedric Charrier, Catherine Rodger, Jennifer Robertson, Aleksandra Kowalczyk, Nicola Shand, Douglas Fraser-Pitt, Derry Mercer and Deborah O'Neil. Cysteamine (Lynovex), a novel mucoactive antimicrobial and antibiofilm agent for the treatment of cystic fibrosis. *Orphanet J Rare Dis*. 2014 Nov 30;9:189 <https://pubmed.ncbi.nlm.nih.gov/25433388/>
59. Neil K. O'Connor, Alex S. Hudson, Steven L. Cobb, Deborah O'Neil, Jennifer Robertson, Vanessa Duncan & Cormac D. Murphy. Novel fluorinated lipopeptides from *Bacillus* Sp. Cs93 via precursor-directed biosynthesis. *Amino Acids*. 2014.46:2745-2752.
60. Derry K Mercer, Lorna Miller, Jennifer Robertson, Linda Turvey and Deborah A O'Neil. Lysine Polymers for the treatment of dandruff. *Toiletries and Cosmetics*. 2014.129 (7):60-70. <https://www.cosmeticsandtoiletries.com/cosmetic-ingredients/actives/article/21835234/lysine-polypeptides-for-dandruff-treatment>
61. D. Mercer, C. Charrier, J. Robertson, A. Kowalczyk, E. Devlin, D. Fraser-Pitt, G. Devereux & D. O'Neil. Ex vivo efficacy of Lynovex[®], a next generation tri-functional candidate cystic fibrosis therapy. *J. Cystic fibrosis*. 2014. 13; S58
62. Deborah A O'Neil & Douglas Fraser-Pitt. Progress towards the next generation of therapeutics for cystic fibrosis. *Future Med Chem*. 2014 Jun;6(9):1067-79.
63. Deborah A. O'Neil. A better fit? Biotech versus Big Pharma in orphan/rare disease drug research. *Exp Opin Orph Drug*. 2014. 2(4); 317-319
64. Derry K Mercer, Jennifer Robertson, Kristine Wright, Lorna Miller, Shane Smith, Colin S Stewart & Deborah A. O'Neil. A Pro-drug Approach to the Use of Coumarins as potential Therapeutics for Superficial Mycoses. *PLoS One*. 2013. 8 (11)
65. Derry K. Mercer & Deborah A. O'Neil. Peptides as the next generation of anti-infectives. *Future Med. Chem*. 2013. 5(3); 315-337.

66. ECFS poster 2012 – C Charrier, C Rodgers, N Shand, D Mercer, D O’Neil. Lynovex, a Novel Mucolytic – Antimicrobial agent for the Treatment of Cystic Fibrosis. *Journal of Cystic Fibrosis*. 11:S75
67. Vanessa M. Duncan & Deborah A. O’Neil. Commercialization of antifungal peptides. *Fungal Biol Rev.*2013 (26); 156-165.
68. Deborah A. O’Neil. Prospects for Peptide Anti-infective Agents. *Innov Pharm Tech*. 2011; 62-66.
69. ICAAC POSTER 2009. V M S Duncan, J Robertson, L Turvey, L Miller, C Charrier, C A Bamford, C S Stewart, D K Mercer, D A. O’Neil. In vitro & ex vivo activity of NP213, a Fungicidal Peptide for the Treatment of Onychomycosis. *Aspergillus & Aspergillosis*. 2009. F1-852. No publication no.
70. C A. Bamford, D B. Galloway, D A. O’Neil. Preclinical Toxicology of NP213, a Novel Fungicidal Peptide for the Treatment of Onychomycosis. *Aspergillus & Aspergillosis*. 2009. F1-854. No publication no
71. E Furrie, S Macfarlane, A Kennedy, J H Cummings, S V Walsh, D A O’Neil, G T Macfarlane. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut*. 2005; 54:242–249
72. Deborah A. O’Neil. Regulation of expression of α -defensins: Endogenous enteric peptide antibiotics. *Molecular Immunology*. 2003. 40(7): 445-450
73. Deborah O’Neil and Lothar Steidler. Cytokines, Chemokines and Growth Factors in the Pathogenesis and Treatment of Inflammatory Bowel Disease. *Adv Exp Med Biol* 2003; 520:252-85
74. Deborah O’Neil and Denise Kelly. Neonatal Nutrition and Immunity. *Dietary and Human Immune Function*. Humana Press. 2003. pp 65-78cv
75. Singh JC, Cruickshank SM, O’Neil D, Conway S, Carding SR, Lodge JPA. Aberrant gene expression in colonic epithelial cells - implications for the pathogenesis of ulcerative colitis. *Br J. Surg*. 2002; 89: 46 Suppl.
76. Bajaj-Elliott M, Fedeli P, and O’Neil D. Interferon-gamma blocks the interleukin-1 and bacterially mediated induction of human beta-defensin 2 expression in gastric and intestinal epithelial cells *Gut*. 2002; 50: 251S.
77. D.A. O’Neil, S. Conway, G. Grant, K.E Garden, E.T Logan, D. Wilson, D. Kelly. Bacterial flagellin, but not LPS, is required for the induction of human β -defensin 2 in intestinal and gastric epithelial cells. *Reprod.Nutr.Dev*. 2002; 42:S14.
78. G. Grant, N.H. McKenzie, M. Duncan, J. Campbell, T.P. King, S. Conway, D.A. O’Neil and D. Kelly. *Bacteroides Thetaiotaomicron* limits the severity of infection caused by *Salmonella enterica* serovar Enteritidis in the rat. *Reprod.Nutr.Dev*. 2002; 42:S14.
79. Deborah O’Neil, Sophie Janssens, Sabine Neiryck, Rudi Beyaert, Erik Remaut and Lothar Steidler. TLR-4 mediates the bacterial induction of mammalian enteric α -defensin expression independently of CD14 and MyD88. *Scand. J. Immunol*. 2001. 54: S76.

80. Mona Bajaj-Elliott, Lothar Steidler and Deborah O'Neil. Interferon- α blocks the interleukin-1 and bacterially mediated induction of human α -defensin-2 expression in gastric and intestinal epithelial cells. *Scand. J. Immunol.* 2001. 54: S76.
81. Deborah O'Neil and Daniel Jones. Genomics and proteomics. *Curr Opin Mol Ther.* 2000. 2(6):621-2.
82. Deborah O'Neil. Viruses as vectors for gene transfer. *Curr Opin Mol Ther.* 2000. 2(5):484-5.
83. Deborah O'Neil. Gene therapy in cancer treatment. *Curr Opin Mol Ther.* 2000. 2(4):359.
84. Deborah O'Neil, Erik Remaut and Lothar Steidler. Bacterial induction of enteric HBD-2 requires TLR4. *Scand. J. Immunol.* 2000. 52:445.
85. Deborah A. O'Neil, Sheri P. Cole, Edith Martin-Porter, Michael P. Housley, Lide Liu, Tomas Ganz and Martin F. Kagnoff. Regulation of human β -defensins by gastric epithelial cells in response to infection with *Helicobacter pylori* or stimulation with interleukin-1. *Inf. Immun.* 2000. 68(9): 5412-5415.
86. O'Neil DA, Cole SP, Martin-Porter E, Liu L, Ganz T, Kagnoff MF. *Helicobacter pylori* and IL-1 upregulate the expression of human beta-defensin (hBD)-2 but not hBD-1 in gastric epithelium. *Gastroenterology.* 118 (4): 3814 Part 1 Suppl. 2000.
87. DA O'Neil, E Martin-Porter, M Anderson, D Elewaut, L Eckmann, T Ganz and MF Kagnoff. Expression and regulation of the human β -defensins hBD-1 and hBD-2 in intestinal epithelium. *J.Immunol.* 1999. 163(12): 6718-24.
88. Lopes LM, Hughson E, Anstee Q, O'Neil D, Katz DR and Chain BM. Vectorial function of major histocompatibility complex class II in a human intestinal cell line 1999. *Immunology* 98(1):16-26
89. O'Neil. D, Swanton C, Jones A, Medd PG, Rayment N and Chain B. γ -IFN downregulates MHC expression and antigen processing in a human B cell line. *J. Immunol* 1999. 162(2):791-798
90. Drakesmith H, O'Neil DA, Sercarz E, Schneider S, Beverly P and Chain BM. Direct priming of T cells against cryptic epitopes by murine dendritic cells following exposure to interleukin-6. *Proc. Natl. Acad. Sci.* 1998. 95:14903-14908
91. DA O'Neil, L Lopes and BM Chain. The interaction between endocytic and antigen processing pathways in the gastrointestinal epithelial cell line, Caco-2. *Immunol.Cell.Biol.* 1997. 75: S77
92. DA O'Neil and BM Chain. Interleukin-6 but not interferon-gamma upregulates antigen presentation in B cells. *Immunology* 1995. 86(1): S125
93. DA O'Neil and BM Chain. Unique processing of antigen by cathepsin E, an aspartic proteinase from the gastrointestinal epithelium - implications in oral tolerance and immunity. *Immunology* 1995. 86(1): S24
94. DA O'Neil and BM Chain. Processing of antigen by cathepsin E, an aspartic proteinase from the gastrointestinal epithelium. *Clin.Immun.Immunopath.* 1995. 76(1): S10